CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 16, 2003
Result type: Reports
Project Number: SR0002-000
Product Line: Reimbursement Review

Generic Name: Atazanavir

Brand Name: Reyataz

Manufacturer: Bristol Myers Squibb

Therapeutic Area: HIV infection

Indications: HIV infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 27, 2004

Recommendation Type: List in a similar manner to other drugs in class